Table III.

Adverse effects and inadequate response reported with Gabapentinoids.

Adverse effects observed in patients who completed the study (n=252)
Drugs	Adverse effects	n (%)	Mean dose ±SD (mg/d)
Pregabalin	Dizziness, Drowsiness, Somnolence	58 (23)	95.43±53.06
	Visual Blurring	3 (1.19)	125.00±90.14
	Ataxia	4 (1.58)	56.25±10.83
	Weight Gain	1 (0.39)	300
Gabapentin	Dizziness, Drowsiness, Somnolence	10 (3.96)	360±171.27
Patients’ non-compliance due to severe adverse effects (n=28)
	n (%)		Mean dose ±SD (mg/d)
Pregabalin	15 (54)		112.00±48.17
Gabapentin	13 (46)		375.68±189.70
Patients with inadequate response (n=24)
Pregabalin	7 (29)		126.21±49.20
Gabapentin	17 (71)		325.58±162.73
Lost to follow up (n=16)
Pregabalin	4 (25)		106.28±80.24
Gabapentin	12 (75)		384.38±177.64